Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q2 2025
Cumberland Pharmaceuticals (CPIX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 8, 2025
Cumberland Pharmaceuticals (CPIX) reported revenue of $10.8M for the second quarter 2025 (Q2 2025), +10% from a year earlier and -7% from the quarter before. Operating margin was -6.9%, net loss $735K (6.8% of revenue).
Cumberland Pharmaceuticals, Q2 2025: revenue $10.8M (+10% year over year), operating margin -6.9%, net loss $735K, operating cash flow $844K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | -7% | +10% |
| Operating profit | −$747K | -158% | — |
| Net earnings | −$735K | -158% | — |
| Operating cash flow | $844K | -78% | — |
| Free cash flow | $817K | -79% | — |
What changed
Revenue was $10.8M in Q2 2025, up 10% year over year and down 7% from the previous quarter. Sancuso was the largest line at 29% of revenue. Sancuso added $930K year over year (up 43%), 94% of the total change. Kristalose declined 33%.
Operating costs exceeded revenue by $747K, an operating margin of -6.9%. Total costs grew 7% against revenue growth of 10%. The fastest-growing cost line was Research & development (+39%). The quarter ended with a net loss of $735K, after a profit of $1.2M the previous quarter.
Operating cash flow was $844K. Non-cash charges added back $1.0M of depreciation and amortization and $81K of share-based compensation. Working capital and other items added $464K. Capital expenditures of $26K left free cash flow of $817K.
Questions
What was Cumberland Pharmaceuticals' revenue in the second quarter 2025?
Cumberland Pharmaceuticals (CPIX) reported revenue of $10.8M for the second quarter 2025 (Q2 2025), +10% from a year earlier and -7% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the second quarter 2025?
Operating loss was $747K (-6.9% of revenue) and net loss $735K.